<a href="https://laohu8.com/S/AORT">Artivion</a> Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million
Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL17872) on November 06, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。